Efficacy of oral calcium pentosan polysulphate for the treatment of osteoarthritis of the canine stifle joint secondary to cranial cruciate ligament deficiency

Abstract

The efficacy of calcium pentosan polysulphate (CaPPS) as a slow-acting drug for the treatment of osteoarthritis of the canine stifle joint, secondary to cranial cruciate ligament deficiency, was tested in a double-blind, placebo-controlled clinical trial over a period of one year. Dogs with the deficiency were treated surgically, matched for bodyweight, and randomly assigned to treatment or placebo groups. Active treatment began six weeks postoperatively and consisted of 10 mg/kg CaPPS orally, once weekly for four weeks, repeated every 12 weeks. The outcome was assessed in terms of function by the dogs' owners, by the radiographical grading of the osteoarthritis, and by the measurement of total sulphated glycosaminoglycans and the 5D4 epitope of keratan sulphate in the synovial fluids of affected joints. There were no differences either in functional outcome or in the radiographical progression of osteoarthritis between the two groups. Fifty-four weeks after surgery, the concentration of 5D4 in synovial fluid (expressed as change from baseline values) had decreased significantly in the treatment group compared with the placebo group (P=0.03).

Systematic review of the management of canine osteoarthritis

“…Pharmacological agents There were 40 studies of pharmacological agents as symptom-modifying agents, structure-modifying agents, or both (Altman and others 1989a, b, Howell and others 1991, Myers and others 1991, 1999, Rogachefsky and others 1993, Fernandes and others 1995, 1998, Vasseur and others 1995, Carney 1996, Read and others 1996, Yu and others 1996, Jovanovic and others 1997, Budsberg and others 1999, 2007, Manicourt and others 1999, Pelletier and others 1999, 2005, Smith and others 1999, Doig and others 2000, Innes and others 2000, Boileau and others 2002, Lipscomb and others 2002, Nell and others 2002, Hazewinkel and others 2003, Moreau and others 2003, 2006, 2007, Behets and others 2004, El Hajjaji and others 2004, Lajeunesse and others 2004, Pardy and others 2004, Peterson and Keefe 2004, Hanson and others 2006, Karsdal and others 2006, Mastbergen and others 2006, Pollmeier and others 2006, Ryan and others 2006, Brainard and others 2007, Mansa and others 2007). …”

Pentosan polysulfate inhibits IL-1β-induced iNOS, c-Jun and HIF-1α upregulation in canine articular chondrocytes

“…Pentosan polysulfate (PPS), a semi-synthetic sulfated polysaccharide derived from wood of beech plant, Fagus sylvatica has been shown to improve synovial and subchondral blood flow, to limit cartilage matrix degeneration, and to stimulate hyaluronic acid and proteoglycan (PGs) synthesis [26–29]. Our laboratory previously showed its involvement in the prevention of inflammatory intracellular responses induced by IL-1β via inhibiting NFkB pathway and the phosphorylation of p38 and ERK but not JNK [30].…”

Spontaneous dog osteoarthritis — a One Medicine vision

“…Academic and private practice veterinary medicine can provide valuable biomedical research data, as referral centres are often equipped with MRI and CT scanners, arthroscopes and state-of-theart pathology and molecular diagnostic capabilities. Academic veterinary centres also pilot advances in the use of anti-inflammatory and pain-modulating OA drug therapies 10,14,15 . In this Review, we summarize research relating to common forms of spontaneous dog OA, focusing on the presentation and genetics of analogous diseases of the hip and knee, within a framework of human OA phenotypes.…”